Related posts
Tech fades in mixed tradingStocks, oil and cryptos rallyOil slides, but stocks hold on China’s weaknessThis summary was created by AI, based on 4 opinions in the last 12 months.
Gilead Sciences Inc. has a mixed outlook from various experts. One reviewer expresses skepticism about investing due to the company's reliance on blockbuster drugs with impending patent expirations, while another highlights a turnaround with accelerating earnings driven by their HIV platform. Another review mentions the stock hitting 52-week highs and appreciates the recent performance, noting a breakout after years of consolidation, though the reviewer remains unsure if this breakout will sustain. However, there is a contrasting opinion that suggests the stock may be overvalued despite a recent bounce back in share prices. Overall, the perspectives indicate a blend of optimism about growth potential, especially in HIV treatments, but caution regarding valuation and long-term viability.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q
In the last year, 4 stock analysts published opinions about GILD-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Gilead Sciences Inc..
Gilead Sciences Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Gilead Sciences Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
4 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.
On 2025-04-02, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $111.89.
He had owned it for 10 years at a time when it had a blockbuster drug that cured hepatitis. Gilead took profits and invested them into HIV drugs. As with other drug companies holding patents on blockbuster drugs with expiry dates, don't buy this one.